Floatz logo

Sotrastaurin

CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma

Novartis PharmaceuticalsSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

271 Active assets in the CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 2/3A
Evomela
Ruijin Hospital
Phase 4BBB
Axicabtagene Ciloleucel
Ruijin Hospital
Phase 4BBB
PREDNISONE TABLETS
Beth Israel Deaconess Medical Center
Phase 4BBB
Inno-206
Beth Israel Deaconess Medical Center
Phase 4BBB

View all 50 →

Same molecule, other indications

Sotrastaurin is also rated in:

uveal melanomaDormant
CCC
Indicative ·
54 / 100
View asset →
prolymphocytic leukemiaDormant
CCC
Indicative ·
53 / 100
View asset →
mantle cell lymphomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →